SymBio Pharmaceuticals Limited (TYO:4582)
Japan
· Delayed Price · Currency is JPY 114.00
-1.00 (-0.87%)
Mar 10, 2026, 9:35 AM JST
SymBio Pharmaceuticals Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -4,776 | -3,806 | -1,195 | 2,106 | 2,032 | Upgrade
|
| Depreciation & Amortization | - | - | 98 | 99 | 93.96 | Upgrade
|
| Other Amortization | 110.28 | - | - | - | 1.95 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 131 | 568 | - | 0.69 | Upgrade
|
| Asset Writedown & Restructuring Costs | 109.27 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 94.71 | - | - | - | 124.27 | Upgrade
|
| Other Operating Activities | 73.76 | 27 | -377 | -420 | -1,048 | Upgrade
|
| Change in Accounts Receivable | 163.48 | 489 | 1,171 | 62 | -1,741 | Upgrade
|
| Change in Inventory | -50.03 | 54 | 237 | -82 | 559.24 | Upgrade
|
| Change in Accounts Payable | -169.38 | -215 | -356 | 662 | -595.78 | Upgrade
|
| Change in Other Net Operating Assets | -131.46 | -96 | -340 | -813 | 711.88 | Upgrade
|
| Operating Cash Flow | -4,576 | -3,416 | -194 | 1,614 | 140.04 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | 1052.51% | - | Upgrade
|
| Capital Expenditures | - | -19 | -204 | -2 | -25.45 | Upgrade
|
| Cash Acquisitions | -0.02 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -82.47 | -27 | -28 | -45 | -38.38 | Upgrade
|
| Other Investing Activities | 6.57 | 43 | -144 | - | -7.01 | Upgrade
|
| Investing Cash Flow | -75.92 | -3 | -376 | -47 | -70.85 | Upgrade
|
| Long-Term Debt Issued | 2,925 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -552.5 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | 2,372 | - | - | - | - | Upgrade
|
| Issuance of Common Stock | 1,256 | 709 | 681 | 630 | 0.9 | Upgrade
|
| Repurchase of Common Stock | -0.05 | - | - | -2 | -68.83 | Upgrade
|
| Other Financing Activities | -6.78 | -1 | -1 | -1 | -4 | Upgrade
|
| Financing Cash Flow | 3,622 | 708 | 680 | 627 | -71.92 | Upgrade
|
| Foreign Exchange Rate Adjustments | -50.2 | 158 | 125 | 213 | 14.21 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | -1 | 14 | - | Upgrade
|
| Net Cash Flow | -1,080 | -2,553 | 234 | 2,421 | 11.48 | Upgrade
|
| Free Cash Flow | -4,576 | -3,435 | -398 | 1,612 | 114.59 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 1306.78% | - | Upgrade
|
| Free Cash Flow Margin | -349.91% | -140.09% | -7.12% | 16.11% | 1.39% | Upgrade
|
| Free Cash Flow Per Share | -91.13 | -76.17 | -9.97 | 40.70 | 2.95 | Upgrade
|
| Cash Interest Paid | 39.24 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | 12.6 | -39 | 354 | 363 | 3.8 | Upgrade
|
| Levered Free Cash Flow | -2,885 | -2,055 | -143.5 | 1,542 | -226.95 | Upgrade
|
| Unlevered Free Cash Flow | -2,901 | -2,055 | -143.5 | 1,542 | -226.95 | Upgrade
|
| Change in Working Capital | -187.39 | 232 | 712 | -171 | -1,065 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.